'What proportion of the people require the vaccine for us to manage this entire COVID-19 situation?'
A dipstick survey covering 30 villages in Rajasthan threw up some worrisome numbers. About 250 children missed their regular vaccination schedule in March alone. These numbers are alarming, since India has around 600,000 villages according to the 2011 census. Sohini Das reports.
'The government had a vaccine from January.' 'The government should have given the vaccine to all population above the age of 45, right from the start.' 'Each state has its own problems, but as far as vaccine coverage in India is concerned, there have been mistakes.'
In another setback to Big Pharma, US drug major Eli Lilly's blockbuster erectile dysfunction drug Cialis (generic name:Tadalafil) has failed to qualify for a product patent in India after the basic constituent of the medicine was found to be a known substance, developed and patented by Indian scientists 32 years ago.
Most foreign drug makers have 100% subsidiaries in India, apart from their listed arms.
Fixed-dose combinations are medicines that come mixed in a certain proportion.
In a boost to India's biggest drugmaker Ranbaxy Laboratories Ltd, an Austrian panel has ruled in the company's favour in a patent litigation against Pfizer involving cholesterol lowering drug 'Lipitor' in that country.
Investors must carefully watch the developments on the MNC pipeline.
Several companies, including Indian units of Abbott Laboratories and Pfizer Inc, and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
NPPA suggests expanding the list of essential medicines whose prices are controlled
Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
The Finance Ministry further said decision on seven FDI proposals has been deferred.
The government has cleared 19 foreign investment proposals, including that of Walt Disney Company and Reckitt Benckiser (India), entailing total investment of Rs 2,326.72 crore (Rs 23.26 billion).
Western drugmakers, including Pfizer Inc, Novartis AG, Roche Holding AG and Sanofi SA, covet a bigger share of the fast-growing Indian drugs market.
We present our alphabet of 2020, pulling in everything you'll remember about this year we'd rather forget.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Sources indicated defence and national security initiatives.
Of the 30-share Sensex pack, 22 ended with losses while NTPC ended flat at Rs 127.30.
The NSE 50-share Nifty spurted 97.25 points, or 0.92 per cent, to 10,715.50
This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
It's a post-truth world for multinational brands and businesses too.
Launches cloud-based version of solution to target mid-size clients in life sciences.
The recall is the latest in a series of problems to hit Ranbaxy, which has had all its India factories stopped from sending drugs and ingredients to the United States.
Unlike India, the US is a free-pricing market.
Merrill Lynch jumps to first from 7th last year in a smaller market; says its focus is larger deals and clients.
To ensure transparency, the Third Eye Cinema Fund has roped in various agencies as auditors and advisors.
Drug major Ranbaxy Laboratories on Thursday said it plans to launch more generic products in the US market with possible marketing exclusivity, while keeping options open for overseas acquisitions to grow its business in various global markets.
It could also ease the burden on the 225 million women in developing countries, says Ari Altstedter.
A certain segment of the US pharma industry have become vocal about Indian policies on domestic content requirements and IPR.
The S&P BSE Sensex gained 115 points to end at 24,338 and the Nifty50 climbed 42 points to close at 7,404.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances